- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT07475676
Effects of Short-term Acute Creatine Supplementation on Power, Speed and Muscular Strengths in Young Football Players
March 11, 2026 updated by: St. Mary's University, Twickenham
Creatine has been widely studies within the strength and conditioning background and has been seen to show positive effects on performance assess the effects of creatine on sports requiring a range of different fitness components to be successful such as football.
Previous research has suggested benefits of creatine supplementation such as increasing PCr (phosphocreatine) stores to aid ATP (adenosine triphosphate) production, increasing muscle water retention resulting in enhanced protein synthesis, reduced muscle damage and anti-inflammation.
Identifying supplements that are scientifically proved to aid performance can help optimise training and develop physical ability of athletes to enhance performance.
Study Overview
Status
Not yet recruiting
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Estimated)
20
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Wiktor Dabrowski, Bsc
- Phone Number: +447526985253
- Email: wiktord839@gmail.com
Study Contact Backup
- Name: Alex Woodhead
- Phone Number: 020-8240-4000
- Email: alex.woodhead@stmarys.ac.uk
Study Locations
-
-
-
London, United Kingdom, TW1 4SX
- St Mary's University Twickenham London
-
Contact:
- Reception Reception
- Phone Number: 020824040000
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
Accepts Healthy Volunteers
No
Description
The inclusion criteria require individuals:
- Male or female between the age of 18-45
- Trained individuals currently playing at a semi-professional (regional) level currently training and competing no more than three times a week
- Free of long-term injuries for the last six months
- Not supplementing creatine within the last 3 months.
- Able to swallow pills
- No medical conditions
Exclusion Criteria:
- Individuals will be excluded from participation if they are under the age of 18 or over the age of 45
- Not currently playing football at a semi-professional (regional) level.
- Train and/or compete more than three times per week
- Have any current injury or have experienced a long-term injury within the previous six months that may affect performance or increase the risk of injury during testing.
- Individuals who have supplemented with creatine within the last three months, - Any medical condition will not be eligible to take part in the study.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Placebo Comparator: Placebo
|
Placebo
|
|
Active Comparator: Creatine Supplementation
|
Creatine Monohydrate
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
The effects of acute creatine supplementation on semi-pro football player speed test results following a seven-day supplementation period.
Time Frame: 7 days
|
Participants will supplement creatine for a seven day period.
Baseline testing will take place before supplementation using a 30m sprint test, it will be measured by the time it took to sprint the 30m (seconds).
Participants will undergo the same test after following 7 days.
The effects of creatine supplementation will be noted by the difference between sprint test scores (seconds).
|
7 days
|
|
The effects of acute creatine supplementation on semi-pro football player countermovement jump (power) results following a seven-day supplementation period.
Time Frame: 7 days
|
Participants will supplement creatine for a seven-day period.
Baseline testing for power will take place before supplementation using a countermovement jump.
Participants will undergo the same test after following 7 days.
The effects of creatine supplementation will be noted by the difference between countermovement jump scores (power).
|
7 days
|
|
The effects of acute creatine supplementation on semi-pro football player lower limb strength test results completed through a 5-RM leg press test following a seven-day supplementation period.
Time Frame: 7 days
|
Participants will supplement creatine for a seven-day period.
Baseline testing will take place before supplementation using a 5-RM leg press, it will be measured by the maximal amount of weight used to complete five reps on the leg press (kg).
Participants will undergo the same test after following 7 days.
The effects of creatine supplementation will be noted by the difference between the maximal amount of weight used to complete five reps on the leg press (kg)t test scores (seconds).
|
7 days
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Estimated)
March 1, 2026
Primary Completion (Estimated)
March 30, 2026
Study Completion (Estimated)
April 13, 2026
Study Registration Dates
First Submitted
February 27, 2026
First Submitted That Met QC Criteria
March 11, 2026
First Posted (Actual)
March 16, 2026
Study Record Updates
Last Update Posted (Actual)
March 16, 2026
Last Update Submitted That Met QC Criteria
March 11, 2026
Last Verified
March 1, 2026
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- SMU_ETHICS_2025-26_229
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Performance Enhancement
-
United States Army Aeromedical Research LaboratoryCompletedPerformance EnhancementUnited States
-
Louisiana State University Health Sciences Center...CompletedMuscle Activation | Performance EnhancementUnited States
-
Coşkun YILMAZCompletedAthletic Performance | Neuromuscular Adaptations | Athletic Performance EnhancementTurkey (Türkiye)
-
Elif TurgutHacettepe UniversityRecruitingShoulder | Athlete | Performance EnhancementTurkey (Türkiye)
-
Ulaş Can YILDIRIMCompletedCognitive Performance | Physical Performance Enhancement | Caffeine and L-theanine InteractionTurkey (Türkiye)
-
Istanbul Topkapi UniversityCompletedCyclists | Performance Enhancement | Isokinetic TestTurkey (Türkiye)
-
Karolinska InstitutetCompletedMental Health | Performance Anxiety | Performance EnhancementSweden
-
Salih ÇABUKCompletedAnaerobic Performance | Athletic Performance Enhancement (Kickboxing) | Strength Endurance | Neuromuscular Power | Nutritional Supplementation (β-Alanine)Turkey (Türkiye)
-
Antonio Molina LopezUniversidad Europea de Madrid; Universidad Pablo de OlavideCompletedAthletic Performance Enhancement | Body Composition Optimization | Nutritional Supplementation in AthletesItaly
Clinical Trials on Placebo
-
SamA Pharmaceutical Co., LtdUnknownAcute Bronchitis | Acute Upper Respiratory Tract InfectionKorea, Republic of
-
National Institute on Drug Abuse (NIDA)CompletedCannabis UseUnited States
-
AkesoNot yet recruitingAtopic DermatitisChina
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyCompletedMale Subjects With Type II Diabetes (T2DM)Germany
-
Heptares Therapeutics LimitedCompletedPharmacokinetics | Safety IssuesUnited Kingdom
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited Kingdom, Netherlands
-
Chong Kun Dang PharmaceuticalUnknownHypertension | DyslipidemiasKorea, Republic of
-
Shijiazhuang Yiling Pharmaceutical Co. LtdXuanwu Hospital, BeijingCompleted
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States